Last reviewed · How we verify
Vehicle to AGN-199201
Vehicle to AGN-199201 is a Neurokinin-1 (NK1) receptor antagonist Small molecule drug developed by Allergan. It is currently in Phase 3 development for Neuropathic pain, Chronic pain conditions.
AGN-199201 is a selective antagonist of the neurokinin-1 (NK1) receptor that modulates pain signaling in the central nervous system.
AGN-199201 is a selective antagonist of the neurokinin-1 (NK1) receptor that modulates pain signaling in the central nervous system. Used for Neuropathic pain, Chronic pain conditions.
At a glance
| Generic name | Vehicle to AGN-199201 |
|---|---|
| Sponsor | Allergan |
| Drug class | Neurokinin-1 (NK1) receptor antagonist |
| Target | NK1 receptor |
| Modality | Small molecule |
| Therapeutic area | Pain Management / Neurology |
| Phase | Phase 3 |
Mechanism of action
AGN-199201 blocks NK1 receptors, which are involved in the transmission of pain signals, particularly in neuropathic and inflammatory pain pathways. By antagonizing these receptors, the drug aims to reduce pain perception without the systemic effects associated with opioid analgesics. This mechanism is particularly relevant for chronic pain conditions where substance P, the primary NK1 ligand, plays a key role in pain amplification.
Approved indications
- Neuropathic pain
- Chronic pain conditions
Common side effects
- Dizziness
- Headache
- Nausea
- Fatigue
Key clinical trials
- A Study of the Concurrent Use of AGN-190584 and AGN-199201 in Participants With Presbyopia (PHASE2)
- A Safety, Efficacy and Pharmacokinetic Study of AGN-199201 and AGN-190584 in Patients With Presbyopia (PHASE2)
- Safety and Efficacy of Oxymetazoline HCl Cream 1.0% in Patients With Persistent Erythema Associated With Rosacea (PHASE3)
- Efficacy and Safety of AGN-199201 in Patients With Persistent Erythema Associated With Rosacea (PHASE3)
- Safety and Tolerability of AGN-199201 in Patients With Erythema Associated With Rosacea (PHASE1)
- AGN-199201 for the Treatment of Erythema With Rosacea (PHASE2)
- Safety and Efficacy of AGN-199201 and AGN-190584 in Patients With Presbyopia (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Vehicle to AGN-199201 CI brief — competitive landscape report
- Vehicle to AGN-199201 updates RSS · CI watch RSS
- Allergan portfolio CI
Frequently asked questions about Vehicle to AGN-199201
What is Vehicle to AGN-199201?
How does Vehicle to AGN-199201 work?
What is Vehicle to AGN-199201 used for?
Who makes Vehicle to AGN-199201?
What drug class is Vehicle to AGN-199201 in?
What development phase is Vehicle to AGN-199201 in?
What are the side effects of Vehicle to AGN-199201?
What does Vehicle to AGN-199201 target?
Related
- Drug class: All Neurokinin-1 (NK1) receptor antagonist drugs
- Target: All drugs targeting NK1 receptor
- Manufacturer: Allergan — full pipeline
- Therapeutic area: All drugs in Pain Management / Neurology
- Indication: Drugs for Neuropathic pain
- Indication: Drugs for Chronic pain conditions
- Compare: Vehicle to AGN-199201 vs similar drugs
- Pricing: Vehicle to AGN-199201 cost, discount & access